Agoracom Blog Home

Posts Tagged ‘small cap’

Kontrol $KNR $KNR.ca $KNR.c $KNRLF Completes Debenture Exchange and Announces Intention to Begin Process of Uplisting to Major North American Stock Exchanges $SNE $MSFT $HON $GOOGL $QCOM

Posted by AGORACOM-JC at 7:22 AM on Wednesday, December 16th, 2020
kontrol-logo
  • Company’s board of directors has authorized management to review the process to graduate the Company from the CSE to the TSX
  • If the Company is successful in uplisting to the TSX, Kontrol intends to, as soon as practical, begin the process of filing a Form F-1 Registration Statement with the Securities and Exchange Commission of the United States, which will enable Kontrol to apply to be listed on the NASDAQ

TORONTO, ON / December 16, 2020 / Kontrol Energy Corp. (CSE:KNR)(OTCQB:KNRLF)(FSE:1K8) (“Kontrol” or “Company“), a leader in smart buildings and cities through IoT, Cloud and SaaS technology, is pleased to announce that it has completed its previously announced debenture exchange (see press release dated June 9, 2020 and November 2, 2020) by private placement. The 2020 Debenture holders exchanged a total of $3,650,000 for 2022 Debentures and new proceeds of $871,000 were raised. The remaining 2020 Debenture balance of $2,061,000 was redeemed in cash by the Company. Each unit is comprised of one $1,000 8% unsecured debenture (and non-convertible) of the Company maturing on October 31, 2022 and 10 common shares.

Paul Ghezzi, CEO of Kontrol, commented:

“With the exchange of the 2020 Debentures we have improved the balance sheet and the Company’s net equity position. As we continue to execute on our business plan, we believe this is an opportune time to begin the graduation process to the senior North American exchanges for an uplisting in 2021.”

Name Change

Further to the passing of a resolution of shareholders at its most recent general and special meeting of shareholders, the Company intends to proceed with a corporate name change to “Kontrol Technologies Corp.”, which is anticipated to be completed prior to December 31, 2020.

Uplisting to TSX, NASDAQ

The Company’s board of directors has authorized management to review the process to graduate the Company from the CSE to the TSX. If the Company is successful in uplisting to the TSX, Kontrol intends to, as soon as practical, begin the process of filing a Form F-1 Registration Statement with the Securities and Exchange Commission of the United States (the “SEC“), which will enable Kontrol to apply to be listed on the NASDAQ.

Completion of any uplisting is subject to meeting certain conditions, as well as the approval of the TSX. There is no assurance that the TSX will approve the listing application or that Kontrol will complete the uplisting as contemplated. There is no assurance that either the SEC or NASDAQ will approve the Company’s respective applications or that Kontrol will complete the listing to the NASDAQ as proposed.

About Kontrol Energy

Kontrol Energy Corp., a Canadian public company, is a leader in smart buildings and cities through IoT, Cloud and SaaS technology. Kontrol Energy provides a combination of software, hardware, and service solutions to its customers to improve energy management, air quality and continuous emission monitoring.

Additional information about Kontrol Energy Corp. can be found on its website at www.kontrolenergy.com and by reviewing its profile on SEDAR at www.sedar.com

For further information, contact:

Paul Ghezzi, Chief Executive Officer
[email protected] or [email protected]
Kontrol Energy Corp.
180 Jardin Drive, Unit 9, Vaughan, ON L4K 1X8
Tel: 905.766.0400, Toll free: 1.844.566.8123

Neither IIROC nor any stock exchange or other securities regulatory authority accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.

Where the Company expresses or implies an expectation or belief as to future events or results, such expectation or belief is based on assumptions made in good faith and believed to have a reasonable basis. Such assumptions include, without limitation, that sufficient capital will be available to the Company and that technology will be as effective as anticipated.

However, forward-looking statements are subject to risks, uncertainties, and other factors, which could cause actual results to differ materially from future results expressed, projected, or implied by such forward-looking statements. Such risks include, but are not limited to, that sufficient capital and financing cannot be obtained on reasonable terms, or at all, that technologies will not prove as effective as expected, that customers and potential customers will not be as accepting of the Company’s product and service offering as expected, and government and regulatory factors impacting the energy conservation industry. In particular, successful development and commercialization of the Kontrol BioCloud Analyzer are subject to the risk that the Kontrol BioCloud Analyzer may not prove to be successful in detecting the virus that causes COVID-19 effectively or at all, uncertainty of timing or availability of any regulatory approvals and Kontrol’s lack of track record in developing products for medical applications.

Accordingly, undue reliance should not be placed on forward-looking statements and the forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement. The forward-looking statements contained herein are made as at the date hereof and are based on the beliefs, estimates, expectations, and opinions of management on such date. Kontrol does not undertake any obligation to update publicly or revise any such forward-looking statements or any forward-looking statements contained in any other documents whether as a result of new information, future events or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required under applicable securities law. Readers are cautioned to consider these and other factors, uncertainties, and potential events carefully and not to put undue reliance on forward-looking information.

SOURCE: Kontrol Energy Corp.

AGORACOM Welcomes Valeo Pharma $VPH.ca $VPHIF With 7 Products To Be Launched In 2021 / 2022 ($45M. Estimated Peak Sales / Year) $HLS.ca $MDP.ca $GUD.ca $RX.ca

Posted by AGORACOM-JC at 3:31 PM on Tuesday, December 15th, 2020

(VPH: CSE) (VPHIF: OTCQB) (VP2: FSE)

www.valeopharma.com

Why Valeo Pharma?

  • Commercial stage revenue generating Canadian pharmaceutical company
  • Approaching EBITDA positive in coming months
  • 9 products currently marketed ($40M. estimated peak sales / year)
  • 7 additional products in pipeline ($45M. estimated peak sales / year)
  • In-license business model, no development or clinical risk
  • $1.5M in quarterly revenue ending July 31, 2020
  • $5.26M in revenue for 9 months ending July 31, 2020

What Exactly Does Valeo Pharma Do?

  • Acquires Canadian rights to commercial stage, innovative and proprietary drugs
  • Commercializes innovative prescription products in Canada
  • Focused on Neurodegenerative Diseases,  Oncology and Hospital Specialty Products
  • Internally manages portfolio through all stages of commercialization

Commercial Portfolio

VPH-Commercial-Portfolio

Here’s just a few products already approved:

BRAND: REDESCA® (BIOSIMILAR)

Launch: Q1-2021

Status: Approved by Health Canada December 2020

Indication: Injectable blood thinner

Market size:  $200M

Peak sales estimate $30 – $40M, sales margin 55 – 60% https://www.youtube.com/embed/XNn29Cx2ToY

BRAND: HESPERCOTM

Launch: Launched in Q4 -2020

Status: Approved by Health Canada

What is it: Anti-Oxidant – Immune system support

How’s it sold: Retail, Online (www.hesperco.com, www.amazon.ca)

Market Size: $500M

hesperco

BRAND: ONSTRYV®

Launch: Q3 2019

Status: Received positive recommendation for public reimbursement in Quebec

Use: Parkinson’s disease, 1st treatment launched in Canada since 2006

Patient base: 100,000 in Canada 2nd chronic neurodegenerative disorder after Alzheimer

Market Size: $20M

%Peak sales estimate $8M, sales margin 65-70 %

Pipeline

Pipeline

The Valeo Model

Company Forecast

  • All portfolio & pipeline products to be on the market by end 2022
  • Solid pipeline composed of “licensed” products
  • Peak Sales reached 2-4 years after market launch
  • From 1 product on the market to 12 in 4 years and more to come
  • Forecast excludes any new product licensing

Hub On AGORACOM / Corporate Profile

CLIENT FEATURE: Innocan Pharma $INNO.ca Developing The Pharmaceutical Guided Missile To Defeat Coronavirus Lung Infections $CGC.ca TLRY $VFF.ca $APHA $OVAT.ca $KHRN.ca

Posted by AGORACOM-JC at 11:38 AM on Tuesday, December 15th, 2020
Innocan-Blog

Innocan Pharma Corporation (INNO: CSE) (IP4:FSE) is developing the pharmaceutical guided missile to defeat coronavirus lung infections. The company specializes in the development of new drug platforms which combine unique properties of Cannabinoids. 

3 Fully Operating Divisions For Investor Diversification

Innocan has 3 fully operating divisions to address the market for Cannabis products.  As a Cannabis investor, why limit yourself to a Company with just one specialty, when Innocan offers you exposure to both the exploding world of cannabis pharma, as well as, a portfolio of patent-pending and launch ready consumer health products.

PHARMACEUTICAL – THE GUIDED MISSILE – Revolutionary technology targeting lungs infected with coronavirus or other viral infections.

CONSUMER RETAIL – DERMA COSMETICS – A premium derma cosmetics brand, manufacturing has commenced with distribution agreements in place.

OVER THE COUNTER (OTC) PRODUCTS FOR PAIN RELIEF – patent-pending CBD pain relief brand received FDA technical validation.

Global Manufacturing / Distribution Agreements

  • Endless Sky Inc. a Canadian large scale Cannabis extractor (Manufacturing and Distribution – Canada)
  • Swiss CBD provider Cloud 9 Switzerland LLC (Distribution – Italy and Switzerland)
  • Active Therapeutics Ltd of Lancashire, United Kingdom (Distribution – UK and Ireland markets)
  • iAmHealth Distribution UG (Distribution – Germany)

Completed Trademark Registration in the EU, UK and Switzerland

  • Completion of the registration of its trademarks: Innocan Pharma, Relief & Go and SHIR in the EU, UK and Switzerland.
  • These trademarks represent Innocan’s OTC and derma cosmetic brand products that were recently launched in the German and UK markets.

Superior Management Team

In the small cap world, the jockey(s) that drive the horse are just as important as the horse itself.  The InnoCan Leadership Group Is Incomparable In The Small Cap World, Comprised Of Leading Israeli Pharmaceutical Executives including:

  • Executive Chairman (Ron Mayron) was the CEO Of Teva Israel, one of the largest generic pharmaceutical companies in the world
  • Co-Founder & VP Business Development (Yoram Drucker) was the Founder of 2 NASDAQ Companies (Pluristem & Brainstorm)
  • Chief Technology Officer (Nir Avram) is a former member of the pharma innovation team at Perrigo, producer of OTC consumer goods and specialty pharma.
  • Chief Executive Officer (Iris Bincovich) has a proven track record in opening global markets, having managed hundreds of successful transactions in OTC, cosmetics and dermatology.

Together they have built one of the most formidable teams in the small cap cannabis world

Hub On AGORACOM / Corporate Profile

Kontrol Energy $KNR $KNR.ca $KNR.c $KNRLF Enters into Distribution Agreement with Grande West to Offer BioCloud Technology Covid-19 Detection Systems for Vicinity Buses $SNE $MSFT $HON $GOOGL $QCOM $SONA.ca

Posted by AGORACOM-JC at 7:26 AM on Tuesday, December 15th, 2020
kontrol-logo
  • Entered into a distribution agreement with Grande West, a Canadian manufacturer of mid-sized multi-purpose transit vehicles for sale in Canada and the United States, to offer BioCloudTM technology to the Vicinity line of buses.
  • Under the terms of the non-exclusive distribution agreement, Grande West will offer the BioCloud solution as an option in its Vicinity LightningTM, Vicinity LT and Vicinity heavy duty bus specifications.
  • Grande West’s existing customers will be notified of the option to retrofit the BioCloud devices into existing fleets across Canada.

TORONTO, ON / December 15, 2020 / Kontrol Energy Corp. (CSE:KNR)(OTCQB:KNRLF)(FSE:1K8) (“Kontrol” or “Company“) is pleased to announce that it has entered into a distribution agreement with Grande West, a Canadian manufacturer of mid-sized multi-purpose transit vehicles for sale in Canada and the United States, to offer BioCloudTM technology to the Vicinity line of buses.

“We are pleased to enter into this agreement with Grande West as we continue to target the important sector of ground transportation with an established and successful bus OEM. We are excited to be working with another disruptive Canadian company, focusing on a transit solution that will make buses safer and reduce risk of potential viral spread for the riders,” stated Paul Ghezzi, CEO Kontrol Energy. “We anticipate that this additional partnership will add another channel for incremental sales as the need for safe detection of airborne viruses in public spaces grows.”

Under the terms of the non-exclusive distribution agreement, Grande West will offer the BioCloud solution as an option in its Vicinity LightningTM, Vicinity LT and Vicinity heavy duty bus specifications. Grande West’s existing customers will be notified of the option to retrofit the BioCloud devices into existing fleets across Canada. United States customers will be serviced by working with Kontrol Energy’s exclusive distributor, United Safety and Survivability Corporation. Pricing will not be disclosed for industry competitive purposes.

William Trainer, President & CEO of Grande West stated, “Grande West is proud to be partnering with Kontrol in working towards making our Vicinity buses safer for all of our end users. The Company is expanding its product lines into Electric Vehicles and lighter duty models and ramping up its U.S. sales and expects significant growth in the coming years. We will do everything we can to offer the safest and most effective transit solutions to our customers.”

As an initial step, Grande West is immediately ordering two of BioCloud units for its offices and operations headquarters in Aldergrove to improve the safety considerations of its employees.

About BioCloudTM

BioCloud is a real-time analyzer designed to detect airborne viruses. It has been designed to operate as a safe space technology by sampling the air quality over time. With a proprietary detection chamber that can be replaced as needed, viruses are detected, and an alert system is created in the Cloud or over local intranet. BioCloud has been designed for spaces where individuals gather including classrooms, offices, retirement homes, hospitals, mass transportation and others.

Additional information about Kontrol BioCloud can be found on its website at www.kontrolbiocloud.com

BioCloud is an air quality technology and not a medical device. The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus).

About Kontrol Energy

Kontrol Energy Corp., a Canadian public company, is a leader in smart buildings and cities through IoT, Cloud and SaaS technology. Kontrol Energy provides a combination of software, hardware, and service solutions to its customers to improve energy management, air quality and continuous emission monitoring.

Additional information about Kontrol Energy Corp. can be found on its website at www.kontrolenergy.com and by reviewing its profile on SEDAR at: www.sedar.com

About Grande West Transportation Group

Grande West Transportation is a Canadian company that designs and engineers mid-size multi-purpose transit vehicles for public and commercial enterprises. Grande West utilizes world-class manufacturing partners to produce the Purpose-Built VicinityTM medium and heavy-duty buses available in electric, CNG, gas and clean diesel drive systems. The Vicinity LightningTM EV with an electric propulsion drive system is available for 2021 deliveries.

The Company has been successful in supplying Canadian municipal transportation agencies and private operators with new buses. Grande West is compliant to Buy America certification, and with a strong distribution chain in the U.S., is actively pursuing opportunities in public and private transit fleet operations that would benefit from Grande West’s vehicles.

www.grandewest.com

www.vicinitybus.com

For further information, contact:

Paul Ghezzi, Chief Executive Officer
[email protected] or [email protected]
Kontrol Energy Corp.
180 Jardin Drive, Unit 9, Vaughan, ON L4K 1X8
Tel: 905.766.0400, Toll free: 1.844.566.8123

Neither IIROC nor any stock exchange or other securities regulatory authority accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.

Where the Company expresses or implies an expectation or belief as to future events or results, such expectation or belief is based on assumptions made in good faith and believed to have a reasonable basis. Such assumptions include, without limitation, that sufficient capital will be available to the Company and that technology will be as effective as anticipated.

However, forward-looking statements are subject to risks, uncertainties, and other factors, which could cause actual results to differ materially from future results expressed, projected, or implied by such forward-looking statements. Such risks include, but are not limited to, that sufficient capital and financing cannot be obtained on reasonable terms, or at all, that technologies will not prove as effective as expected, that customers and potential customers will not be as accepting of the Company’s product and service offering as expected, and government and regulatory factors impacting the energy conservation industry. In particular, successful development and commercialization of the Kontrol BioCloudTM (“BioCloud”) are subject to the risk that the Kontrol BioCloud may not prove to be successful in detecting the virus that causes COVID-19 effectively or at all, uncertainty of timing or availability of any regulatory approvals and Kontrol’s lack of track record in developing products for medical applications.

Accordingly, undue reliance should not be placed on forward-looking statements and the forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement. The forward-looking statements contained herein are made as at the date hereof and are based on the beliefs, estimates, expectations, and opinions of management on such date. Kontrol does not undertake any obligation to update publicly or revise any such forward-looking statements or any forward-looking statements contained in any other documents whether as a result of new information, future events or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required under applicable securities law. Readers are cautioned to consider these and other factors, uncertainties, and potential events carefully and not to put undue reliance on forward-looking information.

SOURCE: Kontrol Energy Corp.

VIDEO – Mountain Valley MD $MVMD.ca Catches Small Cap Fire After #Ivermectin Testimony In US Senate Called “Miraculous Effectiveness” In Prohibiting Transmission Of #COVID-19

Posted by AGORACOM-JC at 4:19 PM on Monday, December 14th, 2020

“It basically obliterates transmission of this virus”  

This was the testimony of  Pierre Kory, M.D., Associate Professor of Medicine at St. Luke’s Aurora Medical Center, delivers passionate testimony during the Senate Homeland Security and Governmental Affairs Committee hearing on “Early Outpatient Treatment: An Essential Part of a COVID-19 Solution, Part II.”

We interviewed Leigh Hughes, newly appointed Advisor to MVMD who will be supporting the Company in the areas of M&A, corporate finance and pharmaceutical licensing, to provide us with further insight as to why the testimony of Dr. Kory is so relevant to MVMD … and why Dr. Kory actually called MVMD last week to discuss the Company’s involvement with Ivermectin.

Mountain Valley MD has traded over 50,000,000 shares in the last 3 trading days, so there is a clear need for information amongst retail investors.

CLIENT FEATURE: Else Nutrition $BABY.ca $BABYF Backed By A $2.7 Billion Dollar Global Nutrition Powerhouse $BYND $VERY.ca $INGR $VEGN $TOFB

Posted by AGORACOM-JC at 12:09 PM on Monday, December 14th, 2020
http://blog.agoracom.com/wp-content/uploads/2020/03/else-square-150x150.png

Else Nutrition Holdings Inc. (BABY: TSXV) (BABYF: OTCQX) (0YF: FSE) is the award winning, plant-based nutrition company for small cap investors. The shift towards plant-based alternatives has opened the food market to new players, and created an opportunity for fast growth in a rapidly expanding space.  Else has fully grasped at this opportunity as seen below.

Highlights include:

  • $CAD 30 Million In Cash
  • Launched 1st Commercial Product Into US Market
  • Backed By A $2.7 Billion Dollar Global Nutrition Company;
  • MOU For International Distribution Of Products
  • “Best Health” Award At Global Food Innovation Summit In Milan;
  • Awarded Patents In 22 Countries, 44 Countries Pending;
  • Executives & Advisors From Globally Renowned Companies & Institutions
  • Distribution agreement with one of the largest and most well regarded national fresh, organic and specialty food distributors in North America
  • Received key Clean Label Certifications for Toddler Nutrition Product
  • Received Key USDA Organic Certification

Else Nutrition’s Complete Nutrition for Toddlers ranked Top-Selling Product on Amazon’s Hot New Releases in Baby and Toddler Formula Category 

Hub On AGORACOM / Corporate Profile

Else Nutrition Holdings is an advertising client of AGORA Internet Relations Corp.

ThreeD Capital $IDK.ca $IDKFF To Disclose Monthly Net Asset Value Per Share $PKK.ca $PKKFF $MTRX.ca $RACMF

Posted by AGORACOM-JC at 7:27 AM on Monday, December 14th, 2020
IDK-square-for-blog
  • Announces that it will begin to publicly disclose unaudited net asset value per share on a monthly basis, commencing with the January 31, 2021 period.
  • This expands on ThreeD’s established practice of releasing NAV on a quarterly basis and reflect our response to shareholder interest in receiving NAV information more frequently.

TORONTO, Dec. 14, 2020 – ThreeD Capital Inc. (“ThreeD” or the “Company”) (CSE:IDK / OTCQB:IDKFF) announces that it will begin to publicly disclose unaudited net asset value per share (“NAV”) on a monthly basis, commencing with the January 31, 2021 period. This expands on ThreeD’s established practice of releasing NAV on a quarterly basis and reflect our response to shareholder interest in receiving NAV information more frequently.

Monthly NAV will be disclosed by the Company in a press release and be available on the Company’s website approximately 15 days after month-end. NAV will be calculated based on unaudited month-end financial information.

NAV is a non-GAAP measure calculated as the value of total assets less the value of total liabilities divided by total number of common shares outstanding, as at a specific date. The term NAV does not have any standardized meaning according to GAAP and therefore may not be comparable to similar measures presented by other companies.

“ThreeD believes that providing monthly NAV updates, will be beneficial to our shareholders by providing information that is useful to understanding our performance”, states Sheldon Inwentash, Chairman and CEO, “This measure will help provide a benchmark to evaluate our business relative to that of our peers”.

About ThreeD Capital Inc.

ThreeD is a publicly-traded Canadian-based venture capital firm focused on opportunistic investments in companies in the junior resources and disruptive technologies sectors.  ThreeD’s investment strategy is to invest in multiple private and public companies across a variety of sectors globally. ThreeD seeks to invest in early stage, promising companies where it may be the lead investor and can additionally provide investees with advisory services and access to the Company’s ecosystem.

For further information:
Gerry Feldman, CPA, CA
Chief Financial Officer and Corporate Secretary
[email protected]
Phone: 416-941-8900 ext 106

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof.

Forward-Looking Statements

This news release contains certain forward-looking statements and forward-looking information (collectively referred to herein as “forward-looking statements”) within the meaning of Canadian securities laws including, without limitation, statements with respect to timing and content of future disclosures of the NAV of the Company. All statements other than statements of historical fact are forward-looking statements. Undue reliance should not be placed on forward-looking statements, which are inherently uncertain, are based on estimates and assumptions, and are subject to known and unknown risks and uncertainties (both general and specific) that contribute to the possibility that the future events or circumstances contemplated by the forward-looking statements will not occur including, without limitation, risks relating to the timing and content of future public disclosures by the Company or related to the fact that the term NAV does not have any standardized meaning according to GAAP and therefore may not be comparable to similar measures presented by other companies. Although the Company believes that the expectations reflected in the forward looking statements contained in this press release, and the assumptions on which such forward-looking statements are made, are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking statements included in this document, as there can be no assurance that the plans, intentions or expectations upon which the forward-looking statements are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause the Company’s actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. The forward-looking statements contained in this news release are made as of the date hereof and the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, except as required by applicable law. The forward-looking statements contained herein are expressly qualified by this cautionary statement.

Kontrol $KNR $KNR.ca $KNR.c $KNRLF to Ship BioCloud Unit to UAE for Field Demonstration and Provides HVAC Connection Upgrade $SNE $MSFT $HON $GOOGL $QCOM $SONA.ca

Posted by AGORACOM-JC at 7:33 AM on Friday, December 11th, 2020
kontrol-logo

Safe Space Technology™

  • Announced that it will be shipping a BioCloud unit to the United Arab Emirates for field demonstration during the week of December 13th. The demonstration is anticipated to run approximately 3 weeks.
  • “The planned shipment of the BioCloud unit to the UAE is based on regional interest in the application of viral detection technology,” says Paul Ghezzi, CEO of Kontrol.

TORONTO, ON / December 11, 2020 / Kontrol Energy Corp. (CSE:KNR)(OTCQB:KNRLF)(FSE:1K8) (“Kontrol” or “Company“) is pleased to announce that it will be shipping a BioCloud unit to the United Arab Emirates for field demonstration during the week of December 13th. The demonstration is anticipated to run approximately 3 weeks.

“The planned shipment of the BioCloud unit to the UAE is based on regional interest in the application of viral detection technology,” says Paul Ghezzi, CEO of Kontrol.

The Company is also pleased to announce that its BioCloud technology will be able to communicate in both modbus and bacnet protocols for integration into heating, cooling and ventilation systems (HVAC) for buildings. Modbus and bacnet are network protocols most commonly used for industrial automation systems and specifically for the connection and integration of electronic equipment. The Company has previously designed and incorporated modbus and bacnet protocols as part of its core energy management and air quality business operations. The software upgrade will be part of all future manufactured units.

“BioCloud will be able to operate as standalone unit or we can integrate with HVAC systems, as may be required, through this upgrade,” says Gary Saunders, VP Kontrol.

About Kontrol BioCloudTM

BioCloud is a real-time analyzer designed to detect airborne viruses. It has been designed to operate as a safe space technology by sampling the air quality over time. With a proprietary detection chamber that can be replaced as needed, viruses are detected, and an alert system is created in the Cloud or over local intranet. BioCloud has been designed for spaces where individuals gather including classrooms, offices, retirement homes, hospitals, mass transportation and others.

Additional information about Kontrol BioCloud can be found on its website at www.kontrolbiocloud.com

BioCloud is an air quality technology and not a medical device. The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus). Safe Space Technology is a Kontrol Trademark.

About Kontrol Energy

Kontrol Energy Corp., a Canadian public company, is a leader in smart buildings and cities through IoT, Cloud and SaaS technology. Kontrol Energy provides a combination of software, hardware, and service solutions to its customers to improve energy management, air quality and continuous emission monitoring.

Additional information about Kontrol Energy Corp. can be found on its website at www.kontrolenergy.com and by reviewing its profile on SEDAR at www.sedar.com

For further information, contact:

Paul Ghezzi, Chief Executive Officer
[email protected] or [email protected]
Kontrol Energy Corp.
180 Jardin Drive, Unit 9, Vaughan, ON L4K 1X8
Tel: 905.766.0400, Toll free: 1.844.566.8123

Neither IIROC nor any stock exchange or other securities regulatory authority accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.

Where the Company expresses or implies an expectation or belief as to future events or results, such expectation or belief is based on assumptions made in good faith and believed to have a reasonable basis. Such assumptions include, without limitation, that sufficient capital will be available to the Company and that technology will be as effective as anticipated.

However, forward-looking statements are subject to risks, uncertainties, and other factors, which could cause actual results to differ materially from future results expressed, projected, or implied by such forward-looking statements. Such risks include, but are not limited to, that sufficient capital and financing cannot be obtained on reasonable terms, or at all, that technologies will not prove as effective as expected, that customers and potential customers will not be as accepting of the Company’s product and service offering as expected, and government and regulatory factors impacting the energy conservation industry. In particular, successful development and commercialization of the Kontrol BioCloud Analyzer are subject to the risk that the Kontrol BioCloud Analyzer may not prove to be successful in detecting the virus that causes COVID-19 effectively or at all, uncertainty of timing or availability of any regulatory approvals and Kontrol’s lack of track record in developing products for medical applications.

Accordingly, undue reliance should not be placed on forward-looking statements and the forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement. The forward-looking statements contained herein are made as at the date hereof and are based on the beliefs, estimates, expectations, and opinions of management on such date. Kontrol does not undertake any obligation to update publicly or revise any such forward-looking statements or any forward-looking statements contained in any other documents whether as a result of new information, future events or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required under applicable securities law. Readers are cautioned to consider these and other factors, uncertainties, and potential events carefully and not to put undue reliance on forward-looking information.

SOURCE: Kontrol Energy Corp.

VIDEO – Datametrex $DM.ca $DTMXF Discusses Record Q3 and YTD Results, Looks Forward To 2021 $PFM.ca $VQS.ca $SPOT.ca $ADK.ca

Posted by AGORACOM-JC at 7:26 PM on Thursday, December 10th, 2020
Webinar logo

Datamerex (DM:TSXV) has the rare benefit that most small cap companies would only dream of …. 2 successful independent divisions that are each capable of being a company maker.

The first division is their Artificial Intelligence driven social media monitoring and discovery product … and this isn’t some basic social media monitoring tool for keywords. Clients include Canadian Federal Government, DRDC, Health Canada, United States Air Force and LOTTE (a $2.6B South Korean multinational conglomerate.

As a result of the highest level security clearances required to do this level of work, Datametrex was well positioned with deep roots in South Korea to add their second, though unintended division of COVID-19 test kit distribution.  Again, this isn’t some small cap stretch trying to capitalize on a trend for the sake of stock promotion. Rather, when the Canadian Government came calling for assistance in importing and distributing COVID-19 test kits, Datametrex stepped up to the task thanks to its security clearances already in place in both countries.

Since then, the company has signed multiple multi-million dollar COVID-19 test kit supply agreements with mining companies, a $20M CAD agreement with the television and film industry and various educational institutions.  

As a result, Datametrex has had its’ best year ever in the first 3 quarters of 2020 as follows:

  • Record revenue of $7.6 million for the nine-month 2020 period compared to $2.6 in 2019
  • Record revenue of $4.9 million was generated in Q3
  • First ever positive EBIDTA quarter

Watch this powerful interview with CEO Marshall Gunter to discuss the year that was … and why he’s so optimistic about 2021.

VIDEO – Kontrol Energy $KNR $KNR.ca $KNR.c $KNRLF Prepares To Scale Real-Time COVID-19 Air Detector With First Distribution Agreements and $500,000 From Canadian Government $SNE $MSFT $HON $GOOGL $QCOM $SONA.ca

Posted by AGORACOM-JC at 4:02 PM on Thursday, December 10th, 2020
kontrol-logo

Kontrol Energy (KNR:CSE) (KNRLF:OTCQB) is the Google NEST of smart building technology, with the Blue Chip client base to prove it.  As such, when COVID-19 started shutting down buildings, arenas and complexes, their announcement the Receipt Of Positive Lab Results for Live COVID-19 Testing was taken very seriously by the investment community, with the stock smashing through to all-time highs and consolidating nicely in the $3.50 range.

Much of that consolidation came as a result of “impatient investors” who unrealistically demanded immediate and big sales agreements for the BioCloud unit, priced at $US 12,000 EACH.  But KNR CEO Paul Ghezzi and his team know that real success comes from building a real foundation – and they did that in a mind boggling 3 months.  We’ve been in the smallcap business long enough to know that pulling off the following in 3 months is damn near impossible, until now:

DISTRIBUTION – On December 1, 2020 KNR announced Entering into Exclusive Distribution Agreement with United Safety and Survivability Corporation for BioCloud Technology Distribution in North America, Australia and New Zealand. The exclusivity applies to the industries defined as buses, rail and locomotive, subways, ambulances, fire trucks, first responder and military vehicles, with applicable associated facilities in the geography of North America , Australia , and New Zealand . The exclusivity period is 12 months with a six month mutual renewal option and is based on 5,000 units of BioCloud per annum, on a best efforts basis, to retain exclusivity. Pricing will not be disclosed for industry competitive purposes. 

In addition, KNR has also entered into two non-exclusive BioCloud distribution agreements covering Ontario and Saskatchewan.

MORE GOVERNMENT FUNDING –  On December 3rd, 2020 the Company announced that it had received an additional $500,000 in research and development funding from the Canadian Federal Government.  This comes after a $50,000 grant earlier this year.  

PATENTS FILED  – On November 30, 2020 KNR announced the filing of 4 patents for the BioCloud technology with 3 patents filed in the USA and 1 patent in Canada .

MANUFACTURING –  KNR has engaged OES Inc. a local design and contract manufacturer in London, Ontario to produce the BioCloud units.  OES Inc. has a long and established history of assisting with the design and manufacturing of complex technology. Initial maximum capacity has been set at 10,000 units per month.

With all its ducks lined up and ready, CEO Paul Ghezzi says Kontrol is now well positioned for commercialization and believes 2021 is going to provide investors what they have long been waiting for.  Well, at least those investors that didn’t think 3 months was an unreasonable amount of time do all of this in.  Everybody else will just have to wait to see BioCloud in a building near them and wonder what could have been.

Watch or listen to this powerful interview with Kontrol Energy CEO, Paul Ghezzi.